Japan IBD therapeutics market is estimated to grow significantly at a CAGR of around 6.2% during the forecast period. The market is mainly driven due to the growing prevalence of IBD in the country due to growing smoking habits. Smoking is one of the major environmental factors leading to an adverse effect on the small and large intestines. In fact, Crohn’s disease is associated positively with smoking while ulcerative colitis is not. Moreover, smoking has a detrimental effect on the clinical course of Crohn’s disease. Therefore, smoking is supporting the prevalence of Crohn’s disease, which as a result is propelling the IBD therapeutics market in Japan. Moreover growing research on the IBD in the country further provides substantial opportunity to the market. 

Japan IBD therapeutics market is segmented on the basis of disease type and treatment type. The disease type segment includes ulcerative colitis and Crohn’s disease. Crohn’s disease segment is estimated to dominate the market. The growth of the segment is attributed to the comparatively higher incidence of Crohn’s disease than ulcerative colitis. For Crohn’s and ulcerative colitis, the development of minimally invasive methods has been evolved with more caution as compared to other colorectal diseases. This is primarily due to disease-related characteristics that are concerned with IBD. The treatment type segment is further segmented into anti-inflammatory drugs and surgery. There is a range of anti-inflammatory drugs used for the treatment of IBD, such as immunosuppressants (methotrexate, ciclosporin, and azathioprine), steroids and biological drugs. Steroids are commonly referred to as Corticosteroids. This enables to reduce inflammation in the digestive tract and provides relief from symptoms of IBD condition. For several people, corticosteroids have a potential anti-inflammatory effect that starts working very rapidly. 

The companies which are contributing to the growth of the Japan IBD therapeutics market include AbbVie Inc., Allergan, PLC, Boehringer Ingelheim International GmbH, Eli Lilly and Co., Daiichi Sankyo Co. Ltd., Mercator Pharmaceutical Solutions  Johnson & Johnson Services Inc., Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Co., Ltd., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market. 

Research Methodology

The market study of Japan IBD therapeutics market is incorporated by extensive primary and secondary research conducted by the research team.  Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

Market Segmentation

1. Japan IBD Market Research and Analysis by Disease Type
2. Japan IBD Market Research and Analysis by Treatment type

The Report Covers

• Comprehensive research methodology of the Japan IBD therapeutics market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the Japan IBD therapeutics market.
• Insights about market determinants which are stimulating the Japan IBD therapeutics market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.